NO933860L - Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon - Google Patents

Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon

Info

Publication number: NO933860L
Authority: NO; Norway
Prior art keywords: extracellular matrix; receptor ligands; leukocyte function; lymphocyte; soluble
Prior art date: 1992-10-30

Application number

NO933860A

Other languages

English (en)

Norwegian (no)

Other versions

NO933860D0 (no

Inventor

Alejandro A Aruffo

N Jan Chalupny

John Marken

Jeffrey A Ledbetter

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-30

Filing date

1993-10-27

Publication date

1994-05-02

1993-10-27 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1993-10-27 Publication of NO933860D0 publication Critical patent/NO933860D0/no

1994-05-02 Publication of NO933860L publication Critical patent/NO933860L/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

NO933860A 1992-10-30 1993-10-27 Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon NO933860L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US96970092A	1992-10-30	1992-10-30

Publications (2)

Publication Number	Publication Date
NO933860D0 NO933860D0 (no)	1993-10-27
NO933860L true NO933860L (no)	1994-05-02

Family

ID=25515876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO933860A NO933860L (no)	1992-10-30	1993-10-27	Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon

Country Status (8)

Country	Link
EP (1)	EP0595659A3 (fr)
JP (1)	JPH072899A (fr)
AU (1)	AU5034493A (fr)
CA (1)	CA2109398A1 (fr)
FI (1)	FI934751A7 (fr)
IL (1)	IL107432A0 (fr)
MX (1)	MX9306682A (fr)
NO (1)	NO933860L (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5981724A (en)	1991-10-25	1999-11-09	Immunex Corporation	DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7405270B2 (en)	1991-10-25	2008-07-29	Immunex Corporation	CD40-Ligand lacking native-pattern glycosylation
US5246113A (en) *	1992-02-11	1993-09-21	Riverwood International Corporation	Carrier for stacked articles
US5683693A (en) *	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
RU2192281C2 (ru)	1996-10-11	2002-11-10	Бристол-Маерс Сквибб Компани	Способы и композиции для иммуномодуляции
CA2308017A1 (fr) *	1997-10-30	1999-05-14	Erik S. Falck-Pedersen	Procede inhibant la reponse immunitaire a un vecteur recombine
SI2428252T1 (sl)	2006-12-28	2015-01-30	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
CN104640568B (zh)	2012-07-18	2016-10-19	阿珀吉尼科斯股份公司	用于治疗mds的cd95信号传导途径的抑制剂
JP2014184804A (ja)	2013-03-22	2014-10-02	Toyota Motor Corp	車両用動力伝達装置の制御装置
EP3076179A1 (fr)	2015-03-30	2016-10-05	Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts	Diagnostic et traitement de gliomes mal différenciés
US20180244792A1 (en) *	2015-09-10	2018-08-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Anti-fibrotic effect of cd70
US20220177841A1 (en)	2019-03-29	2022-06-09	Myst Therapeutics Llc	Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en)	2019-11-27	2023-02-02	Myst Therapeutics, Llc	Method of producing tumor-reactive t cell composition using modulatory agents
EP4512828A3 (fr)	2020-02-27	2025-05-14	Turnstone Biologics Corp.	Méthodes d'enrichissement et de croisement ex vivo de cellules t tumorales réactives et compositions connexes
WO2026044087A1 (fr)	2024-08-21	2026-02-26	Shape Therapeutics Inc.	Stabilité cellulaire accrue pour la production de vaa
WO2026073032A1 (fr)	2024-09-27	2026-04-02	Shape Therapeutics Inc.	Constructions pour une production améliorée d'aav

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3149289A (en) *	1988-03-18	1989-09-21	Rockefeller University, The	Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
US5057604A (en) *	1988-08-03	1991-10-15	Washington University	Novel monoclonal antibodies
CA2000048A1 (fr) *	1988-10-03	1990-04-03	Edward F. Plow	Peptides et anticorps inhibant la liaison integrine-ligand
US5169930A (en) *	1990-01-05	1992-12-08	La Jolla Cancer Research Foundation	Fibronectin receptor
WO1991019511A1 (fr) *	1990-06-18	1991-12-26	The General Hospital Corporation	LUTTE CONTRE LES REACTIONS IMMUNITAIRES/INFLAMMATOIRES CELLULAIRES DES INTEGRINES β2

1993
- 1993-10-27 CA CA002109398A patent/CA2109398A1/fr not_active Abandoned
- 1993-10-27 NO NO933860A patent/NO933860L/no unknown
- 1993-10-27 MX MX9306682A patent/MX9306682A/es unknown
- 1993-10-27 FI FI934751A patent/FI934751A7/fi not_active Application Discontinuation
- 1993-10-28 IL IL107432A patent/IL107432A0/xx unknown
- 1993-10-29 EP EP93308688A patent/EP0595659A3/fr not_active Withdrawn
- 1993-10-29 JP JP5272526A patent/JPH072899A/ja active Pending
- 1993-10-29 AU AU50344/93A patent/AU5034493A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0595659A3 (fr)	1995-01-11
FI934751A0 (fi)	1993-10-27
JPH072899A (ja)	1995-01-06
CA2109398A1 (fr)	1994-05-01
EP0595659A2 (fr)	1994-05-04
FI934751L (fi)	1994-05-01
FI934751A7 (fi)	1994-05-01
AU5034493A (en)	1994-05-12
MX9306682A (es)	1994-04-29
IL107432A0 (en)	1994-01-25
NO933860D0 (no)	1993-10-27

Similar Documents

Publication	Publication Date	Title
NO933860L (no)	1994-05-02	Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon
Marsters et al.	1992	Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.
EP0568925A3 (fr)	1995-03-15	Modulation de l'activité du récepteur de TNF.
IL114615A0 (en)	1995-11-27	Modulators of the function of fas receptors and other proteins
ATE247667T1 (de)	2003-09-15	Gdnf-rezeptor und dessen verwendung
ATE314479T1 (de)	2006-01-15	Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
EP0835447A4 (fr)	1999-06-02	Nouveaux peptides et nouvelles compositions modulant l'apoptose
IL217265A0 (en)	2012-02-29	Use of transmembrane activator, calcium modulator and taci-immunoglobulin fusion proteins for manufacture of a medicament for treating sjogren's syndroem
WO1998003552A3 (fr)	1998-06-25	Proteine de fusion d'un peptide de complexe majeur d'histocompatibilite multivalent permettant la modulation de fonction specifiques de lymphocytes t
PL312989A1 (en)	1996-05-27	Therapeutic derivatives of peptides
BR0011342A (pt)	2002-03-05	Métodos para a modulação de diabetes tipo 2, para modular a resistência à insulina, para alìvio de hiperlipidemia e para tratamento de hiperuricemia em um mamìfero, e, composição farmacêutica
DE69733081D1 (de)	2005-05-25	Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
NZ332879A (en)	2000-09-29	Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
DK0760851T3 (da)	2008-11-10	Tumor-nekrose-faktor receptor-associeret-faktor
NZ514091A (en)	2004-01-30	Vascular adhesion molecules and modulation of their function
WO2000001820A3 (fr)	2000-02-24	Molecules d'acide nucleique codant pour les co-activateurs des recepteurs d'hormones nucleaires
BG109537A (en)	2007-11-30	FUNCTION MODULATORS OF RECEPTORS OF TNF / NGF RECIPE FAMILY AND OTHER PROTEINS
YU54692A (sh)	1995-10-03	Hemijska jedinjenja
DE60126654D1 (de)	2007-03-29	Modulatoren der aktivität von g-protein gekoppelten rezeptor kinasen
MX9605579A (es)	1998-02-28	Factores asociados con el receptor del factor de la necrosis tumoral.
WO1995023217A2 (fr)	1995-08-31	Traitement du diabete sucre et conversion des signaux d'un recepteur d'insuline
ATE386803T1 (de)	2008-03-15	Intrazelluläre glukocortikoid-induzierte leucin- zipper modulatoren von mechanismen des apoptotischen zelltodes
Miller	1982	A NEW ARGININE-SPECIFIC PHOTOAFFINITY LABEL FOR THE EPIDERMAL GROWTH FACTOR RECEPTOR.
Barinov et al.	1995	Effect of selective activation of central serotoninergic systems on the course of the early post-traumatic period
MX9605531A (es)	1998-02-28	Modulador de receptores de la superfamilia de factor de necrosis tumoral/factor de crecimiento de nervio y receptores oligomericos solubles de la superfamilia de factor de necrosis tumoral/factor de crecimiento necrotico.